Home › Targets › VEGF receptors
VEGF receptors (2 companies · 12 programs)
Companies with an active program directed at VEGF receptors.
- CABOMETYX — Renal Cell Carcinoma Approved
- CABOMETYX — Hepatocellular Carcinoma Approved
- CABOMETYX — Differentiated Thyroid Cancer Approved
- CABOMETYX — Pancreatic Neuroendocrine Tumors Approved
- CABOMETYX — Extra-Pancreatic Neuroendocrine Tumors Approved
- zanzalintinib — Colorectal Cancer NDA Submitted
- zanzalintinib — Non-Clear Cell Renal Cell Carcinoma Phase 3
- zanzalintinib — Renal Cell Carcinoma Phase 3
- zanzalintinib — Neuroendocrine Tumors Phase 3
- zanzalintinib — Meningioma Phase 2
- DURAVYU — Wet Age-Related Macular Degeneration Phase 3
- DURAVYU — Diabetic Macular Edema Phase 3
